We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+27.17%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.66B
AUM Growth
+$374M
Cap. Flow
+$32.2M
Cap. Flow %
1.94%
Top 10 Hldgs %
47.85%
Holding
212
New
55
Increased
41
Reduced
36
Closed
38
Avg Time Held Equity + Options
2.1 quarters
Top 10 Avg Time Held Equity + Options
2.8 quarters
Top 20 Avg Time Held Equity + Options
3 quarters
Avg Time Held Equity only
2.2 quarters
Top 10 Avg Time Held Equity only
2.9 quarters
Top 20 Avg Time Held Equity only
3 quarters

Sector Composition

Rank Sector Weight
1 Healthcare 81.96%
2 Miscellaneous 17.3%
3 Consumer Staples 0.52%
4 Financials 0.09%
5 Technology 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
ESPR icon
176
DELISTED
Esperion Therapeutics
ESPR
– –
-102
Closed -$9.98K –
LH icon
177
Labcorp
LH
$25.4B
– –
-2,277
Closed -$247K –
MDT icon
178
Medtronic
MDT
$119B
– –
-5,000
Closed -$390K –
MNKD icon
179
CALL
MannKind Corp
MNKD
$981M
– –
-20
Closed -$1K –
PRPO icon
180
Precipio
PRPO
$40.4M
– –
0
– -$1K
2015 Q2
0 quarters
RDNT icon
181
RadNet
RDNT
$5.63B
– –
-26,525
Closed -$223K –
RGEN icon
182
PUT
Repligen
RGEN
$11.1B
– –
-100,000
Closed -$3.04M –
UTHR icon
183
United Therapeutics
UTHR
$23.3B
– –
-1,481
Closed -$255K –
VNDA icon
184
CALL
Vanda Pharmaceuticals
VNDA
$260M
– –
-100,000
Closed -$930K –
VNDA icon
185
PUT
Vanda Pharmaceuticals
VNDA
$260M
– –
-100,000
Closed -$930K –
CTLT icon
186
DELISTED
CATALENT, INC.
CTLT
– –
-6,429
Closed -$200K –
ALIM icon
187
DELISTED
Alimera Sciences
ALIM
– –
-15,460
Closed -$1.16M –
EIGR
188
CALL
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-1,054
Closed -$8.99M –
EIGR
189
PUT
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-222
Closed -$1.89M –
RAD
190
DELISTED
Rite Aid Corporation
RAD
– –
-1,253
Closed -$218K –
LCI
191
DELISTED
Lannett Company, Inc.
LCI
– –
-1,098
Closed -$297K –
WCG
192
DELISTED
Wellcare Health Plans, Inc.
WCG
– –
-2,690
Closed -$246K –
ONCE
193
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-15,000
Closed -$1.16M –
ALDR
194
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-150,000
Closed -$4.33M –
EXAC
195
DELISTED
Exactech Inc
EXAC
– –
-7,905
Closed -$203K –
SCAI
196
DELISTED
Surgical Care Affiliates, Inc.
SCAI
– –
-7,020
Closed -$241K –
AMSG
197
DELISTED
Amsurg Corp
AMSG
– –
-3,328
Closed -$205K –
AEGR
198
DELISTED
Aegerion Pharmaceuticals
AEGR
– –
-381,100
Closed -$9.97M –
DYAX
199
PUT
DELISTED
DYAX CORPORATION
DYAX
– –
-400,000
Closed -$6.7M –
PCYC
200
DELISTED
PHARMACYCLICS INC
PCYC
– –
-12,000
Closed -$3.07M –

Similar funds

Perceptive Advisors's Q2 2015 Portfolio in Review

As of Q2 2015, Perceptive Advisors held 212 positions worth $1.66B, up 29% from $1.29B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors's Q2 2015 filing shows 55 new, 41 increased, 36 reduced and 38 closed positions. Its largest new stake was Ignyta, Inc.: 1,967,600 shares worth $29.7M. The largest sale was Neurocrine Biosciences, an estimated $19.4M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 84% a quarter earlier, followed by Miscellaneous and Consumer Staples.

  • Perceptive Advisors's largest Q2 2015 buy was Ignyta, Inc.: 1,967,600 shares worth $29.7M.
  • Perceptive Advisors added most to Viatris in Q2 2015, an estimated $14.8M increase.
  • Perceptive Advisors's biggest Q2 2015 reduction was Neurocrine Biosciences, cutting an estimated $19.4M.
  • Perceptive Advisors fully exited bluebird bio in Q2 2015, selling an estimated $16.3M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $1.66B portfolio in Q2 2015.
  • Perceptive Advisors opened 55 new positions and closed 38 in Q2 2015.
  • Perceptive Advisors's portfolio value rose 29% quarter-over-quarter to $1.66B.

Based on Perceptive Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.